TSX:GUD - Post Discussion
Post by
gudisgood on Aug 17, 2022 3:51am
The Gilead Portfolio
Here’s what Samira said about the Gilead portfolio in the Q4/21 earnings call:
So on the termination of agreements, what we did, we know that we -- when it comes to our HIV and HCV portfolio, we did announce that we are transitioning out of those products during the year. And it's going to have a couple of points not significant on the top line. And it's really a normal course of looking at our portfolio, what's the strategic products, what's the growth and profitability, and we determined it didn't make sense for us to continue to be promoting those products, and we came to an agreement with Gilead on that.
"A couple of points"… so 2% out of last year’s revenue is roughly $5M.
Be the first to comment on this post